Signifor
(Pasireotide Diaspartate)Phase 2Small molecule
Signifor is one of 24 small molecule programs targeting Hypoglycemia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
23
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Hypoglycemia
#DrugCompanyPhaseTrials
1Aldactone
PfizerApproved
NOVOLIN R
Novo NordiskApproved
Avelox
BayerApproved
Narcan
SScienture
Approved
Symlin
AstraZenecaApproved
Proglycem
TevaApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Luxiq
SSchering-Plough
Approved
Reglan
IIstituto Clinico Humanitas
Phase 2
Avexitide
AAmylyx Pharmaceuticals Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
CAR1 trial
Regulatory
FDA Approval Timeline[4]
Dec 14, 2012
SIGNIFOR
NDA NDA200677
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pasireotide Diaspartate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRECORDATI GROUP